Dynavax Technologies (NASDAQ:DVAX) Hits New 1-Year High - Time to Buy?

Dynavax Technologies Co. (NASDAQ:DVAX - Get Free Report) hit a new 52-week high on Friday . The stock traded as high as $14.05 and last traded at $13.73, with a volume of 398164 shares. The stock had previously closed at $13.33.

Wall Street Analyst Weigh In

Several brokerages have issued reports on DVAX. The Goldman Sachs Group cut shares of Dynavax Technologies from a "neutral" rating to a "sell" rating and dropped their price objective for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a report on Friday. HC Wainwright restated a "buy" rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday. Finally, StockNews.com upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Monday.

Dynavax Technologies Stock Performance

The stock's 50 day moving average price is $12.83 and its two-hundred day moving average price is $12.06. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of 74.50 and a beta of 1.32.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. On average, analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Hedge Funds Weigh In On Dynavax Technologies

Several hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its holdings in Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 1,169 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 2,034 shares in the last quarter. US Bancorp DE grew its stake in Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 2,034 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Dynavax Technologies during the 4th quarter valued at about $35,000. Finally, Capital Performance Advisors LLP acquired a new position in Dynavax Technologies during the third quarter worth about $45,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.